Physician profile
Edward Champey
NPI 1467458836
$1,500.07
in general payments reported to CMS, 2019-2025
19 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $261 · 2021: $147 · 2022: $381 · 2023: $101 · 2024: $81.38 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $363.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $441.62 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $237.50 | 2019-2025 | Xtampza |
| Biotronik Nro, INC. | $145.84 | 2025 | Prospera |
| Boston Scientific Corporation | $126.91 | 2019 | |
| Stimwave Technologies Incorporated | $112.50 | 2019 | |
| Horizon Therapeutics Plc | $60.98 | 2019-2022 | |
| Janssen Biotech, INC. | $47.88 | 2023 | Stelara, Remicade, Simponi Aria |
| Abbvie INC. | $45.86 | 2022-2023 | Botox |
| Allergan, INC. | $43.67 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.38 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $36.80 | 2023 | Seglentis |
| Ibsa Pharma INC. | $29.19 | 2021 | |
| Avanos Medical | $25.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.26 | 2025 | Entyvio |
| Depuy Synthes Sales INC. | $18.91 | 2024 | Monovisc |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.63 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $16.99 | 2022 | |
| Zyla Life Sciences, INC. | $14.47 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.99 | 2024 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Champey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.